title: Efficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis.
abstract: BACKGROUND
  Celecoxib is an effective treatment for osteoarthritis (OA). However, information on its efficacy and safety profile in different racial/ethnic groups is limited. Noticeable differences among racial groups are found in other disease states, but a thorough investigation of OA is lacking. The objective of this study was to determine if celecoxib 200 mg once daily is as effective as naproxen 500 mg twice daily in the treatment of OA of the knee in Hispanic patients.
  
  
  METHODS
  Hispanic patients aged ≥45 years with knee OA were randomized to receive celecoxib 200 mg once daily, naproxen 500 mg twice daily, or placebo for 6 weeks. The primary efficacy variable was the change in Patient's Assessment of Arthritis Pain at 6 weeks compared with baseline. Secondary variables were change in Patient's and Physician's Global Assessments of Arthritis from baseline to week 6/early termination, change in Western Ontario and McMaster Universities OA Index (WOMAC) from baseline to week 6/early termination, change in American Pain Society pain score, Pain Satisfaction Scale, Patient Health Questionnaire (PHQ-9), and measurements of upper gastrointestinal tolerability.
  
  
  RESULTS
  In total, 239 patients completed the trial (96 celecoxib, 96 naproxen, 47 placebo). Celecoxib was as effective as naproxen in reducing OA pain (least squares mean change from baseline [standard error] -39.7 [2.7] for celecoxib and -36.9 [2.6] for naproxen). Patient's and Physician's Global Assessments of Arthritis, WOMAC scores, upper gastrointestinal tolerability, Pain Satisfaction Scale, and PHQ-9 showed no statistically significant differences between the celecoxib and naproxen groups. The incidence of adverse events and treatment-related adverse events were similar among the treatment groups.
  
  
  CONCLUSIONS
  Celecoxib 200 mg once daily was as effective as naproxen 500 mg twice daily in the treatment of signs and symptoms of knee OA in Hispanic patients. Celecoxib was shown to be safe and well tolerated in this patient population.
authors.affiliation: Pfizer Inc, New York, NY, USA.
authors.forename: Margaret Noyes
authors.initials: MN
authors.lastname: Essex
authors.affiliation: Pfizer Inc, New York, NY, USA.
authors.forename: Regina
authors.initials: R
authors.lastname: Behar
authors.affiliation: Pfizer Inc, New York, NY, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: O'Connell
authors.affiliation: Pfizer Inc, New York, NY, USA.
authors.forename: Pritha Bhadra
authors.initials: PB
authors.lastname: Brown
keywords: cyclo-oxygenase-2; ethnicity; nonsteroidal anti-inflammatory drugs; race